NCT07311122Not yet recruiting
Endocrine Therapy Base on 21-gene RS
Comparison of Endocrine Therapy Plus Ovarian Function Suppression and Chemotherapy Based on 21-gene RS in Young Age (≤ 50) Women (CUSTOM): Multi-center Registry Study
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
Among patients aged ≤50 years with hormone receptor-positive, HER2-negative breast cancer and pathologic nodal stage pN0-1-limited to those with an Oncotype DX® Recurrence Score (RS) of 11-25 for pN0 and ≤25 for pN1-, we will investigate the followings: i) Real-world patterns of adjuvant therapy (systemic chemotherapy and endocrine therapy) and radiotherapy according to N stage and Oncotype DX® RS. ii) Clinicopathologic characteristics of each patient subgroup by adjuvant treatment modality and RS category. iii) Survival outcomes and independent prognostic factors according to RS. iv) Survival analyses by adjuvant treatment modality, stratified by RS category, clinical risk, and N stage. Through these analyses, we aim to establish clinical evidence on whether endocrine therapy combined with ovarian function suppression (OFS) can substitute for adjuvant chemotherapy in HR+/HER2- patients with pN0-1 disease within the above RS ranges, and-if so-to define the patient subsets for whom this substitution is appropriate.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 16 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Gangnam Severance Hospital
- NCT number
- NCT07311122
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 1 Jan 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Insufficient or unclear data regarding the type of adjuvant therapy received.
- Receipt of neoadjuvant systemic therapy prior to surgery.
Other illness
- Hormone receptor-negative or HER2-positive disease.
- History of another malignancy treated before the breast cancer diagnosis, except for thyroid cancer and non-melanoma skin cancer.
- Bilateral breast cancer.
Lab values
- Postmenopausal status at diagnosis, defined as any of the following:
- Prior bilateral oophorectomy before the breast cancer diagnosis (considered postmenopausal).
- Prior unilateral oophorectomy alone is not considered postmenopausal (classified as premenopausal).
- Bilateral oophorectomy performed after breast cancer surgery for therapeutic purposes is not an exclusion; such patients will be categorized as having received ovarian function suppression (OFS).
- Serum FSH ≥ 30 mIU/mL.
Other
- Evidence of distant (systemic) metastasis at diagnosis.
Who the study is looking for
- Histologically confirmed breast cancer.
- Age ≤50 years at initial diagnosis.
- Premenopausal at diagnosis, defined as any of the following:
- History of menstruation within 6 months prior to diagnosis. B. Serum FSH \< 30 mIU/mL. C. If criteria A or B are unavailable, women aged ≤50 years are considered premenopausal.
- Underwent curative-intent breast cancer surgery between January 2012 and December 2021.
- Pathologic tumor stage pT1-pT3 after surgery.
- Pathologic nodal stage pN0-pN1 after surgery.
- Hormone receptor-positive disease by immunohistochemistry (IHC): estrogen receptor (ER) and/or progesterone receptor (PR) positive (≥1% positive cells or Allred score ≥3).
- HER2-negative disease per ASCO/CAP guidelines: IHC 0 or 1+; if IHC 2+, in situ hybridization (FISH or SISH) negative.
- Oncotype DX® performed, meeting one of the following Recurrence Score (RS) ranges:
- pN0: RS 11-25. B. pN1: RS ≤25.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.